| John A Mcknight, MD | |
|
2000 Mon Health Medical Park Drive, Suite 2300, Morgantown, WV 26505-0000 | |
| (304) 599-8802 | |
| (304) 599-5607 |
| Full Name | John A Mcknight |
|---|---|
| Gender | Male |
| Speciality | Cardiovascular Disease (cardiology) |
| Experience | 30 Years |
| Location | 2000 Mon Health Medical Park Drive, Morgantown, West Virginia |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1972694503 | NPI | - | NPPES |
| 001719437 | Other | WV | BCBS |
| 0082170000 | Medicaid | WV |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | 18556 (West Virginia) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| United Hospital Center | Bridgeport, WV | Hospital |
| St Joseph's Hospital | Buckhannon, WV | Hospital |
| West Virginia University Hospitals | Morgantown, WV | Hospital |
| Davis Medical Center | Elkins, WV | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| United Hospital Center Inc | 8123936010 | 209 |
News Archive
Star Scientific, Inc. announced that on Friday, February 19 the company filed an application with the Food & Drug Administration for approval to market Ariva-BDL™ as a "modified risk" tobacco product under the Family Smoking Prevention and Tobacco Control Act of 2009. This submission is the first such application to be filed with the Tobacco Products Center of the FDA, which has been established to oversee all aspects of tobacco regulation outlined in the 2009 Act.
AstraZeneca today announced top-line results of OSKIRA-4, a Phase IIb monotherapy study of fostamatinib, the first kinase inhibitor with selectivity for SYK (spleen tyrosine kinase) in development as an oral treatment for rheumatoid arthritis (RA).
Pioneering research led by the University of Stirling could play a vital role in reducing the prevalence of "snail fever" - a debilitating infection that affects more than 200 million people worldwide.
A team of researchers from Indiana University School of Medicine, Regenstrief Institute and Purdue University, led by Richard Holden, PhD, is testing a new app, called Brain Safe, designed to help people reduce their exposure to a common class of drugs linked to Alzheimer's disease.
› Verified 5 days ago
| Entity Name | United Hospital Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1760965586 PECOS PAC ID: 8123936010 Enrollment ID: O20031212000802 |
News Archive
Star Scientific, Inc. announced that on Friday, February 19 the company filed an application with the Food & Drug Administration for approval to market Ariva-BDL™ as a "modified risk" tobacco product under the Family Smoking Prevention and Tobacco Control Act of 2009. This submission is the first such application to be filed with the Tobacco Products Center of the FDA, which has been established to oversee all aspects of tobacco regulation outlined in the 2009 Act.
AstraZeneca today announced top-line results of OSKIRA-4, a Phase IIb monotherapy study of fostamatinib, the first kinase inhibitor with selectivity for SYK (spleen tyrosine kinase) in development as an oral treatment for rheumatoid arthritis (RA).
Pioneering research led by the University of Stirling could play a vital role in reducing the prevalence of "snail fever" - a debilitating infection that affects more than 200 million people worldwide.
A team of researchers from Indiana University School of Medicine, Regenstrief Institute and Purdue University, led by Richard Holden, PhD, is testing a new app, called Brain Safe, designed to help people reduce their exposure to a common class of drugs linked to Alzheimer's disease.
› Verified 5 days ago
| Entity Name | United Physicians Care Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1891863874 PECOS PAC ID: 6103814017 Enrollment ID: O20040706001382 |
News Archive
Star Scientific, Inc. announced that on Friday, February 19 the company filed an application with the Food & Drug Administration for approval to market Ariva-BDL™ as a "modified risk" tobacco product under the Family Smoking Prevention and Tobacco Control Act of 2009. This submission is the first such application to be filed with the Tobacco Products Center of the FDA, which has been established to oversee all aspects of tobacco regulation outlined in the 2009 Act.
AstraZeneca today announced top-line results of OSKIRA-4, a Phase IIb monotherapy study of fostamatinib, the first kinase inhibitor with selectivity for SYK (spleen tyrosine kinase) in development as an oral treatment for rheumatoid arthritis (RA).
Pioneering research led by the University of Stirling could play a vital role in reducing the prevalence of "snail fever" - a debilitating infection that affects more than 200 million people worldwide.
A team of researchers from Indiana University School of Medicine, Regenstrief Institute and Purdue University, led by Richard Holden, PhD, is testing a new app, called Brain Safe, designed to help people reduce their exposure to a common class of drugs linked to Alzheimer's disease.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| John A Mcknight, MD Po Box 1615, Morgantown, WV 26507-1615 Ph: (304) 599-8802 | John A Mcknight, MD 2000 Mon Health Medical Park Drive, Suite 2300, Morgantown, WV 26505-0000 Ph: (304) 599-8802 |
News Archive
Star Scientific, Inc. announced that on Friday, February 19 the company filed an application with the Food & Drug Administration for approval to market Ariva-BDL™ as a "modified risk" tobacco product under the Family Smoking Prevention and Tobacco Control Act of 2009. This submission is the first such application to be filed with the Tobacco Products Center of the FDA, which has been established to oversee all aspects of tobacco regulation outlined in the 2009 Act.
AstraZeneca today announced top-line results of OSKIRA-4, a Phase IIb monotherapy study of fostamatinib, the first kinase inhibitor with selectivity for SYK (spleen tyrosine kinase) in development as an oral treatment for rheumatoid arthritis (RA).
Pioneering research led by the University of Stirling could play a vital role in reducing the prevalence of "snail fever" - a debilitating infection that affects more than 200 million people worldwide.
A team of researchers from Indiana University School of Medicine, Regenstrief Institute and Purdue University, led by Richard Holden, PhD, is testing a new app, called Brain Safe, designed to help people reduce their exposure to a common class of drugs linked to Alzheimer's disease.
› Verified 5 days ago
Rohma Shamsi, M.D. Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 1 Medical Center Drive, Morgantown, WV 26506 Phone: 304-293-4125 | |
Islam Younes, Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 1 Medical Center Dr, Morgantown, WV 26506 Phone: 855-988-2273 | |
Dr. David Weissman, M. D. Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 1 Stadium Drive, Morgantown, WV 26506 Phone: 304-598-4800 Fax: 304-293-6963 | |
Dr. Madhavi Kadiyala, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1 Medical Center Dr, Morgantown, WV 26506 Phone: 304-598-4000 | |
Dr. Swapna Gayam, M.D Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1 Medical Center Drive, Morgantown, WV 26506 Phone: 304-293-4123 Fax: 304-293-2135 | |
Monika Maximilliane Holbein, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1 Medical Center Dr, Morgantown, WV 26506 Phone: 304-594-4000 | |
Nour Daboul, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1 Medical Center Dr, Morgantown, WV 26506 Phone: 855-988-2273 |